191 related articles for article (PubMed ID: 22216211)
1. Enrichment of variations in KIR3DL1/S1 and KIR2DL2/L3 among H1N1/09 ICU patients: an exploratory study.
La D; Czarnecki C; El-Gabalawy H; Kumar A; Meyers AF; Bastien N; Simonsen JN; Plummer FA; Luo M
PLoS One; 2011; 6(12):e29200. PubMed ID: 22216211
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory natural killer cell receptor KIR3DL1 with its ligand Bw4 constraints HIV-1 disease among South Indians.
Maruthamuthu S; Rajalingam R; Pandian K; Madasamy S; Manoharan M; Pitchai L; Murugesan A; Mariakuttikan J
AIDS; 2018 Nov; 32(18):2679-2688. PubMed ID: 30289808
[TBL] [Abstract][Full Text] [Related]
3. The differential impact of natural killer (NK) cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in-vitro HIV infection.
Lisovsky I; Isitman G; Tremblay-McLean A; Song R; DaFonseca S; Lebouchẻ B; Routy JP; Bruneau J; Bernard NF
Clin Exp Immunol; 2016 Dec; 186(3):336-346. PubMed ID: 27506421
[TBL] [Abstract][Full Text] [Related]
4. High-throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real-time PCR.
Koehler RN; Walsh AM; Moqueet N; Currier JR; Eller MA; Eller LA; Wabwire-Mangen F; Michael NL; Robb ML; McCutchan FE; Kijak GH
Tissue Antigens; 2009 Jul; 74(1):73-80. PubMed ID: 19522772
[TBL] [Abstract][Full Text] [Related]
5. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
[TBL] [Abstract][Full Text] [Related]
6. KIR3DL1 alleles and their epistatic interactions with human leukocyte antigen class I influence resistance and susceptibility to HIV-1 acquisition in the Pumwani sex worker cohort.
Luo M; Czarnecki C; Nebroski M; Kimani J; Bernard N; Plummer FA
AIDS; 2018 Apr; 32(7):841-850. PubMed ID: 29280757
[TBL] [Abstract][Full Text] [Related]
7. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
8. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3.
Moesta AK; Norman PJ; Yawata M; Yawata N; Gleimer M; Parham P
J Immunol; 2008 Mar; 180(6):3969-79. PubMed ID: 18322206
[TBL] [Abstract][Full Text] [Related]
9. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.
Frazier WR; Steiner N; Hou L; Dakshanamurthy S; Hurley CK
J Immunol; 2013 Jun; 190(12):6198-208. PubMed ID: 23686481
[TBL] [Abstract][Full Text] [Related]
10. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer.
He Y; Bunn PA; Zhou C; Chan D
Oncotarget; 2016 Dec; 7(50):82104-82111. PubMed ID: 27893413
[TBL] [Abstract][Full Text] [Related]
11. The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.
Kiani Z; Dupuy FP; Bruneau J; Lebouché B; Retière C; Geraghty DE; Bernard NF
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511383
[TBL] [Abstract][Full Text] [Related]
12. Killer immunoglobulin receptor genes and their HLA-C ligand are associated with Type 1 diabetes in an Eastern Indian population.
Sanjeevi S; Sun C; Kanungo A; Sanjeevi CB
Diabet Med; 2016 Jan; 33(1):91-6. PubMed ID: 26031759
[TBL] [Abstract][Full Text] [Related]
13. Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires.
Crum KA; Logue SE; Curran MD; Middleton D
Tissue Antigens; 2000 Oct; 56(4):313-26. PubMed ID: 11098931
[TBL] [Abstract][Full Text] [Related]
14. A Higher Frequency of NKG2A+ than of NKG2A- NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not They Coexpress KIR3DL1.
Lisovsky I; Isitman G; Song R; DaFonseca S; Tremblay-McLean A; Lebouché B; Routy JP; Bruneau J; Bernard NF
J Virol; 2015 Oct; 89(19):9909-19. PubMed ID: 26202228
[TBL] [Abstract][Full Text] [Related]
15. Putative role of KIR3DL1/3DS1 alleles and HLA-Bw4 ligands with end stage renal disease and long term renal allograft survival.
Prakash S; Sarangi AN; Alam S; Sonawane A; Sharma RK; Agrawal S
Gene; 2017 Dec; 637():219-229. PubMed ID: 28942035
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of Killer Ig-like Receptors and the Risk of Glioblastoma.
Choi H; Baek IC; Park SA; Park JS; Jeun SS; Kim TG; Ahn S
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510895
[TBL] [Abstract][Full Text] [Related]
17. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
18. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
Bakker AB; Phillips JH; Figdor CG; Lanier LL
J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
[TBL] [Abstract][Full Text] [Related]
19. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute viral encephalitis.
Tuttolomondo A; Colomba C; Di Bona D; Casuccio A; Di Raimondo D; Clemente G; Arnao V; Pecoraro R; Ragonese P; Aiello A; Accardi G; Maugeri R; Maida C; Simonetta I; Della Corte V; Iacopino DG; Caruso C; Cascio A; Pinto A;
Oncotarget; 2018 Apr; 9(25):17523-17532. PubMed ID: 29707126
[TBL] [Abstract][Full Text] [Related]
20. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402.
Sharma D; Bastard K; Guethlein LA; Norman PJ; Yawata N; Yawata M; Pando M; Thananchai H; Dong T; Rowland-Jones S; Brodsky FM; Parham P
J Immunol; 2009 Oct; 183(7):4569-82. PubMed ID: 19752231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
